In medical terms, PMP most commonly refers to pseudomyxoma peritonei, a rare cancer-like condition in which mucus-producing cells spread across the lining of the abdomen. It affects roughly 3.2 people per million each year. You may also see PMP used as shorthand for prescription monitoring program, an electronic database that tracks controlled substance prescriptions. Which meaning applies depends entirely on context: oncology and surgical settings use PMP for pseudomyxoma peritonei, while pharmacy and primary care settings use it (along with the longer abbreviation PDMP) for prescription drug monitoring.
Pseudomyxoma Peritonei: The Cancer Connection
Pseudomyxoma peritonei is a condition where mucus-producing cells break free from a tumor and spread throughout the peritoneal cavity, the membrane-lined space that holds your stomach, intestines, and other abdominal organs. These cells deposit sticky, gel-like mucin in predictable locations within the abdomen, gradually filling the space with a thick, jelly-like substance. This is why PMP is sometimes called “jelly belly.”
In the vast majority of cases, the source is a tumor in the appendix. Less commonly, it can originate from mucus-producing tumors in the ovary, colon, or pancreas, but the appendix is now accepted as the primary site in both men and women.
What Causes PMP at the Cellular Level
PMP is driven by specific genetic mutations that push appendiceal cells toward uncontrolled growth and excessive mucus production. The most significant is a mutation in the KRAS gene, detected in 58 to 94 percent of PMP cases. This mutation triggers unregulated cell growth and appears in both low-grade and high-grade forms of the disease.
A second mutation, in the GNAS gene, directly increases mucus production. It appears far more often in low-grade PMP than in high-grade disease. High-grade PMP, which behaves more aggressively, tends to carry different mutations: changes in the TP53 gene (a well-known tumor suppressor) and in cell-cycle signaling pathways that are also common in colorectal cancer. The specific combination of mutations a tumor carries helps explain why some PMP cases progress slowly over years while others are more aggressive.
Symptoms and How PMP Is Found
PMP typically starts with no symptoms at all. Because mucus accumulates gradually, the disease can grow for months or years before anyone notices. When symptoms do appear, they tend to be vague: general abdominal discomfort, bloating, or a feeling of fullness. As more mucus builds up, visible abdominal swelling develops.
A retrospective analysis of 217 PMP patients found that the most common way people first presented was with acute appendicitis (27%), followed by abdominal distension (23%). Another 14% were discovered incidentally during investigations for hernias, particularly inguinal hernias. Women may develop palpable ovarian masses. In advanced stages, the sheer volume of mucus can compress the bowel, causing obstruction, malnutrition, and even difficulty breathing as pressure pushes upward against the diaphragm.
When doctors tap the abdominal fluid during diagnosis, it often comes out as a thick, yellowish, gel-like substance rather than the clear fluid seen in typical abdominal swelling. That distinctive finding is a strong clue pointing toward PMP.
How PMP Is Treated
The standard treatment combines two procedures done together: cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC). During cytoreductive surgery, the surgeon removes all visible tumor deposits and mucus from the abdominal cavity. This can mean stripping affected sections of the peritoneal lining and removing portions of organs where disease has attached. Immediately after, heated chemotherapy solution is circulated directly inside the abdomen to destroy any microscopic cancer cells that surgery could not reach.
This is a major operation. It can take many hours and requires significant recovery time. In some cases, patients receive several rounds of standard chemotherapy before surgery to shrink the disease first. The decision about timing depends on how extensive the disease is and the patient’s overall health.
Survival and Outlook
A 22-year study from a single institution found that patients who underwent both CRS and HIPEC had a median survival of about 92 months (nearly 8 years), with a 5-year survival rate of 62%. The 10-year survival rate across all PMP patients managed at that center, including those who did not receive the full combined treatment, was 23%. Outcomes vary considerably depending on whether the disease is low-grade or high-grade and how completely surgeons can remove visible disease.
PMP as Prescription Monitoring Program
In pharmacy and prescribing contexts, PMP refers to a prescription monitoring program, more formally called a prescription drug monitoring program (PDMP). These are state-run electronic databases that track every prescription filled for controlled substances, particularly opioids, benzodiazepines, and stimulants. Every U.S. state operates one.
The primary purpose is safety. When a clinician checks the database before writing a prescription, they can see whether a patient is already receiving controlled substances from other providers. This helps identify patients who may be at risk for overdose or who may be receiving dangerous combinations of medications. It also fills gaps when a patient’s medication history is unavailable, such as during emergency visits or transitions between providers.
Impact on Opioid Prescribing
States that implemented comprehensive PDMP mandates, requiring prescribers to check the database before writing opioid prescriptions, saw meaningful results. Between 2011 and 2016, Medicaid data showed that comprehensive mandates were associated with an 8.9% reduction in opioid prescriptions, dropping from about 161 to 147 prescriptions per quarter per 1,000 enrollees. The reduction was concentrated in the most potent opioids (Schedule II drugs like oxycodone and hydromorphone), which fell by 7.4%. Prescriptions for less potent opioids did not change significantly.
At the same time, prescriptions for buprenorphine, a medication used to treat opioid addiction, were slightly higher in states with comprehensive mandates. This suggests that monitoring programs may be helping shift the prescribing landscape toward treatment rather than just restricting access.